Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

Acta Orthopaedica

Volumn 79, Issue 2, 2008, Pages 269-280

  Ström, Oskar ^a   Borgström, Fredrik ^a,b   Zethraeus, Niklas ^c   Johnell, Olof ^d   Lidgren, Lars ^d   Ponzer, Sari ^e   Svensson, Olle ^f   Abdon, Peter ^g   Ornstein, Ewald ^h   Ceder, Leif ⁱ   Thorngren, Karl Göran ^d   Sernbo, Ingemar ^d   Jönsson, Bengt ^c  

^a Innovus   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g Ystad Hospital   (Sweden)

^h Hassleholm Kristianstad Hospitals   (Sweden)

ⁱ HELSINGBORG HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; NONSTEROID ANTIINFLAMMATORY AGENT; VITAMIN D;

ADULT; AGED; ARTICLE; ECONOMIC ASPECT; FEMALE; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; QUALITY OF LIFE; RISK REDUCTION; SWEDEN; VERTEBRA FRACTURE; WRIST FRACTURE; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; HIP FRACTURE; MIDDLE AGED; PATHOLOGIC FRACTURE; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SPINE FRACTURE; TIME; WRIST INJURY;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; FEMALE; FRACTURES, SPONTANEOUS; HEALTH CARE COSTS; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SPINAL FRACTURES; SWEDEN; TIME FACTORS; WRIST INJURIES;

EID: 44249116046     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/17453670710015094     Document Type: Article

References (41)

1. Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004a; 34 (6): 1064-71.
2. Borgstrom F, Johnell O, Kanis J A, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004b; 22 (17): 1153-65.
3. Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting : Based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006a; 17 (12): 1781-93.
4. Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006b; 17 (5): 637-50.
5. Borgstrom F, Sobocki P, Strom O, et al. The societal burden of osteoporosis in Sweden. Bone 2007; 40 (6): 1602-9.
6. Brazier J E, Green C and Kanis J A. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002; 13 (10): 768-76.
7. Briggs A H, Wonderling D E, Mooney C Z Pulling costeffectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6 (4): 327-40.
8. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37 (1): 53-72.
9. Burstrom K, Johannesson M, Diderichsen F Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10 (7): 621-35.
10. De Laet C E, van Hout B A, Burger H, et al. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 1999; 10 (1): 66-72.
11. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35(11): 1095-108.
12. Dolan P, Torgerson D J The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8 (6): 611-7.
13. Gabriel S E, Tosteson A N, Leibson C L, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002; 13 (4): 323-30.
14. Gujarati D N. Basic Econometrics. Singapore, McGraw Hill 1995.
15. Haentjens P, Autier P, Barette M, et al. The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg (Am) 2001; 83 (4): 493-500.
16. Janzon M, Levin L A, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The fast revascularisation during in stability in coronary artery disease. Eur Heart J 2002; 23 (1): 31-40.
17. Johnell O, Kanis J A, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005; 16 (2): 222-8.
18. Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol (Suppl) 1996; 103: 30-8.
19. Kanis J A, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11 (8): 669-74.
20. Kanis J A, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005; 16 (1): 15-25.
21. Koeck C M, Schwappach D L, Niemann F M, et al. Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Klin Wochenschr 2001; 113 (10): 371-7.
22. Liljegren G, Karlsson G, Bergh J, et al. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol 1997; 8 (8): 757-63.
23. Lippuner K, Golder M. Greiner R Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int (Suppl 2) 2005; 16: S8-S17.
24. Melton L J, 3rd, Gabriel S E, Crowson C S, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14 (5): 383-8.
25. Neter J, Kutner M H, Nachtsheim C J, et al. Applied Linear Statistical Models. Chicago, McGraw-Hill 1996.
26. Nurmi I, Narinen A, Luthje P, et al. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg 2003; 123 (10): 551-4.
27. Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15 (7): 1384-92.
28. Reginster J Y, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15 (5): 507-14.
29. SBU Osteoporos-prevention, diagnostik och behandling, rapport Nr 165 2003 Stockholm
30. SCB Average hourly prices in the private sector,Statistiska Centralbyån (Statistics Sweden). 2004 cited 2005-01-11, from http://www.ssd.scb.se/databaser/makro/MainTable.asp?yp=tansss&xu= C9233001&omradekod=AM&omra detext=Arbetsmarknad&lang=1
31. Stadsledningskontoret Stockholms stads budgetavräkning. 2003 cited 2005-05-20, from www.stockholm.se
32. Strom O, Borgstrom F, Sen S S, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int (epub ahead of print) 2007.
33. Wackerly D, Mendenhall W, Schaeffer R. Mathematical Statistics with Applications. New York, Duxbury Press 1996.
34. Wiktorowicz M E, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12 (4): 271-8.
35. Wong M K, Arjandas, Ching L K, et al. Osteoporotic hip fractures in Singapore--costs and patient's outcome. Ann Acad Med Singapore 2002; 31 (1): 3-7.
36. Vägverket Vägverkets samhällsekonomiska kalkymodell. Ekonomisk teori och värderingar 1997, Stockholm.
37. Zethraeus N, Gerdtham U G. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 1998; 14 (2): 255-67.
38. Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 1997; 68 (1): 13-7.
39. Zethraeus N, Borgström F, Johnell O, et al. Costs and Quality of Life Associated with Osteoporosis Related Fractures - Results from a Swedish Survey 2002, Stockholm
40. Zethraeus N, Borgström F, Jönsson B, et al. A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden - results based on the Women's Health Initiative randomised controlled trial. Working Paper Series in Economics and Finance at the Stockholm School of Economics, 2004, Working paper No. 571. 2004; http://swopec.hhs.se/hastef/papers/hastef0571.pdf.
41. Zethraeus N, Strom O, Borgstrom F. What is the risk of institutionalization after hip fracture? Poster at ECCEO, Vienna, Volume 17, Supplement 1 / March, 2006.